Lada Nuzhna

In this engaging discussion, Elliot Hirshberg, a venture capitalist focused on biotech platforms, and Lada Nuzhna, founder of General Control and biotech analyst, dive into the staggering costs of drug development, revealing it's now $2.5 billion per approval. They explore how China’s fast-tracked trials are reshaping global competitiveness and the significant impact of regulations. The duo muses on how future biotechs might leverage innovative modalities and advanced AI to navigate these challenges and potentially reduce costs.

Lada Nuzhna, Founder and CEO of General Control, specializes in epigenetic therapies for age-related diseases. She shares her fascinating journey from physics to aging research, driven by a passion for extending healthy life. Lada discusses the transformative power of the epigenome and her innovative approach to disease-driving gene expression. With insights on funding, early human trials in China, and the challenges of aging research, she emphasizes the importance of agile biotech teams. Her personal story of growing up in Eastern Ukraine adds depth to her visionary ambitions in longevity.

Lada Nuzhna, researcher, Thiel fellow and founder who has funded $34M+ in longevity science and now builds epigenetic editing therapeutics. She discusses evolutionary views of aging and antagonistic pleiotropy. Talk covers why current models and methylation clocks are limited, the promise and risks of programmable epigenetic editing delivered by LNPs, and how funding and incentives shape biotech for aging.